2009
DOI: 10.1007/978-1-59745-416-2_24
|View full text |Cite
|
Sign up to set email alerts
|

Epidemiology of Lung Cancer Prognosis: Quantity and Quality of Life

Abstract: Primary lung cancer is very heterogeneous in its clinical presentation, histopathology, and treatment response; and like other diseases, the prognosis consists of two essential facets: survival and quality of life (QOL). Lung cancer survival is mostly determined by disease stage and treatment modality, and the five-year survival rate has been in a plateau of 15% for three decades. QOL is focused on life aspects that are affected by health conditions and medical interventions; the balance of physical functionin… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

2
85
1
4

Year Published

2010
2010
2023
2023

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 110 publications
(92 citation statements)
references
References 94 publications
2
85
1
4
Order By: Relevance
“…In contrast, mortality from heart disease, the leading cause of death, declined almost 2.5-fold over the same period (2). The patient survival has been in a plateau for three decades (3), with a 5-year relative survival rate of less than 18% in most countries (4). The efficacy of chemotherapy in lung cancer is limited by the rapid development of cancer cell resistance during treatment.…”
mentioning
confidence: 99%
“…In contrast, mortality from heart disease, the leading cause of death, declined almost 2.5-fold over the same period (2). The patient survival has been in a plateau for three decades (3), with a 5-year relative survival rate of less than 18% in most countries (4). The efficacy of chemotherapy in lung cancer is limited by the rapid development of cancer cell resistance during treatment.…”
mentioning
confidence: 99%
“…(4,5) Metastasis to these organs frequently causes severe symptoms, such as pain, paresis, and dyspnea, and decreases patients' quality of life. (6) Approximately 15% of lung tumors are classified as small-cell lung cancer (SCLC); these tumors grow and metastasize to multiple organs much faster than non-small-cell lung cancer (NSCLC).(7) Although initially sensitive to conventional chemotherapy and radiotherapy, SCLC tumors eventually relapse and become refractory to conventional chemotherapy agents.(8) In addition, although several molecularly targeted drugs, such as the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors gefitinib and erlotinib and the angiogenesis inhibitor bevacizumab, are successful in the treatment of NSCLC, no effective molecularly targeted drugs are currently available for SCLC. Therefore, novel therapeutic methods are essential for improving the poor prognosis of patients with this disease.…”
mentioning
confidence: 99%
“…(4,5) Metastasis to these organs frequently causes severe symptoms, such as pain, paresis, and dyspnea, and decreases patients' quality of life. (6) Approximately 15% of lung tumors are classified as small-cell lung cancer (SCLC); these tumors grow and metastasize to multiple organs much faster than non-small-cell lung cancer (NSCLC). (7) Although initially sensitive to conventional chemotherapy and radiotherapy, SCLC tumors eventually relapse and become refractory to conventional chemotherapy agents.…”
mentioning
confidence: 99%
“…Lung adenocarcinoma is most common form and constitutes about 50% of NSCLC [2]. Despite the significant advances in lung cancer diagnosis and treatment, the prognosis of these patients remains dismal, with 5 years survival rates less than 10% [3]. There occurs frequent relapse with metastasis even in the patients who have undergone complete surgical resection.…”
Section: Introductionmentioning
confidence: 99%